Diffuse Cutaneous Systemic Sclerosis research hub
7 indexed studies · 4 currently recruiting
- recruitingPHASE2
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
This study looks at Brentuximab vedotin for severe scleroderma. It's for people who improved on the treatment before but whose condition worsened after stopping it. Researchers want to see if restarting the treatment is safe and helpful.
Canada - recruitingPHASE2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
This study is looking into a new medicine called Ianalumab for people in the UK with a specific type of scleroderma called diffuse cutaneous systemic sclerosis. It aims to see if the drug is safe and helps with symptoms, compared to a dummy treatment.
United States · Argentina · Austria - ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis [HZNP-HZN-825-301]
This study is testing a new medicine, Fipaxalparant, for people with a serious skin condition called diffuse cutaneous systemic sclerosis. It aims to see if the medicine can improve lung function and other symptoms over about a year.
Romania · Austria · Germany - recruitingPHASE2
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This study is testing a new medicine, MTX-474, for people with a serious skin condition called diffuse cutaneous systemic sclerosis (dcSSc). Researchers want to see if it's safe and helps improve symptoms. It involves regular IV infusions and check-ups.
United States · Australia · France - active not recruitingPHASE2
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
This study looks at a new drug, tulisokibart, for people with a lung condition called interstitial lung disease (ILD) linked to scleroderma. We want to see if it's safe and helps improve the condition.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
This study is looking at a new medicine called Fipaxalparant for people with a serious skin condition called diffuse cutaneous systemic sclerosis. It's a second-stage trial to see how well it works and if it's safe over about a year.
Portugal · Greece · Germany - recruitingPHASE1, PHASE2
Controlling Hyperactive Immunity With Long-lived Lymphocytes
This study tests a new treatment, QEL-005, for severe rheumatoid arthritis and systemic sclerosis. It aims to see if it's safe and helps improve symptoms. QEL-005 uses your own modified white blood cells to calm an overactive immune system.
United Kingdom